加强多学科瘤护理:为比利时多学科瘤咨询会议提供结构化工具的可行性
Nadine Boesten1, Melissa De Regge2, Hannes Vanpoecke3
1European Patient's Forum, Rue des Deux Églises 14, Brussels 1000, Belgium; Department of Marketing, Innovation and Organisation, Faculty of Economics and Business Administration, Ghent University, Tweekerkenstraat 2, Ghent 9000, Belgium.
Journal of cancer policy
|October 30, 2025
概括
结构化工具可以增强瘤护理中的多学科团队会议 (MDTM),但它们的成功实施取决于当地环境和支持性政策. 整合这些工具需要注意团队动态和数字框架,以获得高效,以患者为中心的结果.
科学领域:
- 在瘤学瘤学.
- 医疗保健管理的管理
- 临床信息学 临床信息学
背景情况:
- 多学科团队会议 (MDTM) 在瘤学中至关重要,但在效率和以患者为中心方面面临挑战.
- 现有的 MDTM 结构化工具往往缺乏与医院工作流程的一致整合.
研究的目的:
- 评估在多学科瘤咨询 (MOC) 中实施两个验证的工具 (MDT-QuIC检查清单和MDT-MeDiC复杂性工具) 的可行性.
- 评估这些工具对MOC组织和以患者为中心的影响.
主要方法:
- 在比利时五家医院的十个MOC中进行了可行性研究.
- 使用MDT-MODe观测仪器进行基线评估.
- 通过反复观察和对MOC主席的采访来评估实施情况.
主要成果:
- 基线MOC显示心理社会讨论和护士参与有限.
- 发现MDT-QuIC对结构有帮助,但由于时间限制,应用不一致.
- MDT-MeDiC被认为太资源密集,无法常规使用;实施成功程度因当地因素而异.
结论:
- 结构化工具可以改善MOC组织,但可行性取决于上下文.
- 更广泛的采用需要解决团队组成,准备工作流程和政策整合.
- 数字框架和激励是有效,以患者为中心的瘤治疗的关键.
相关概念视频
Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


